Compare

Compare stocks side by side

Pick up to 3 companies to see where each one is stronger or weaker.

ALPMYSNY

Area by area

Overall Quant Score

How does it look overall? (out of 100)

ALPMY

73/100

SNY

60/100

Quality

Is it a profitable, well-run business?

ALPMY

6.5/10

SNY

3.9/10

Growth

Is the company growing?

ALPMY

6.3/10

SNY

4.6/10

Valuation

Is the price reasonable? (higher = cheaper)

ALPMY

10.0/10

SNY

9.4/10

Risk

How risky are the shares? (higher = lower risk)

ALPMY

8.1/10

SNY

7.9/10

Momentum

Is the share price trending up?

ALPMY

7.1/10

SNY

6.3/10

Financial strength

Is the balance sheet healthy?

ALPMY

6.9/10

SNY

4.9/10

The balanced view

Model-generated

Astellas Pharma Inc.

This company scores above average, with a reasonable valuation and a relatively low-risk profile.

Leads on: quality, growth, valuation, risk, momentum, financial strength

Best feature: reasonable valuation (PEG: 0.04)

Watch out: weakest area: analyst view (Analyst buy share: 67%)

Sanofi

This company scores above average, with a reasonable valuation and a relatively low-risk profile, although its profitability is thin.

Leads on: no single area

Best feature: reasonable valuation (Price / FCF: 5.4x)

Watch out: profitability is thin (Return on equity (TTM): 5.5%)

Different strengths suit different goals — a higher score in one area doesn’t make a stock the better choice for everyone.